Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oliceridine - Trevena

Drug Profile

Oliceridine - Trevena

Alternative Names: OLINVO; TRV 130A; TRV-130

Latest Information Update: 02 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trevena
  • Class Analgesics; Pyridines; Small molecules; Spiro compounds; Thiophenes
  • Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute pain

Most Recent Events

  • 20 Nov 2019 Trevena initiates enrolment in a phase I pharmacokinetic trial in mild/moderate hepatic impairment patients in USA before November 2019
  • 20 Nov 2019 Additional efficacy and adverse events data from the phase III ATHENA-1 trial in Post operative pain released by Trevena
  • 04 Nov 2019 Top-line efficacy & adverse events data from a QT interval study in Acute pain released by Trevena
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top